Get the Stockscreener App
0.805
5.26%
-0.0447
After Hours:
.82
0.015
+1.86%
Atossa Therapeutics Inc Stock (ATOS) Latest News
Atossa Therapeutics Congratulates Board Director Dr. Tessa - GlobeNewswire
What is HC Wainwright's Estimate for ATOS FY2029 Earnings? - MarketBeat
Do investors need to be concerned about Atossa Therapeutics Inc (ATOS)? - US Post News
Financial Metrics Unveiled: Atossa Therapeutics Inc (ATOS)’s Key Ratios in the Spotlight - The Dwinnex
Equities Analysts Set Expectations for ATOS FY2029 Earnings - Defense World
Atossa Therapeutics (NASDAQ:ATOS) Given "Buy" Rating at HC Wainwright - MarketBeat
JPMorgan Chase & Co. Acquires 95,643 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
HC Wainwright Reiterates Buy Rating for Atossa Therapeutics (NASDAQ:ATOS) - Defense World
Atossa Genetics stock hits 52-week low at $0.75 - MSN
Atossa Genetics stock hits 52-week low at $0.75 By Investing.com - Investing.com Canada
Atossa Therapeutics Will Not Appeal PTAB Decision on Review of Patent Covering Endoxifen - Marketscreener.com
Troy Minerals Inc. (TROY-CN) QuotePress Release - The Globe and Mail
Atossa Therapeutics faces patent setback, continues development - Investing.com
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent - GlobeNewswire
Atossa's Patent Strategy Shift: New Endoxifen Patent Reinforces 118+ Protected Claims - StockTitan
Option Volatility And Earnings Report For January 2731 - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Atossa Therapeutics reports progress in breast cancer treatments - Investing.com India
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - The Manila Times
Atossa Therapeutics reports progress in breast cancer treatments By Investing.com - Investing.com South Africa
Atossa's Endoxifen Shows Breakthrough 23.5% Breast Density Reduction in Phase 2 Cancer Trial - StockTitan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stake Raised by Barclays PLC - Defense World
Jane Street Group LLC Trims Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (NASDAQ: ATOS) vs. NLS Pharmaceutics (NASDAQ: NLSP): A Comparative Analysis - HPBL
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
The Hidden Connection: Dr. Steven Quay on Alcohol and Cancer Risk - Cville Right Now
Atossa Therapeutics Applauds U.S. Surgeon General’s - GlobeNewswire
Surgeon General Links Alcohol to 44,000 Annual Breast Cancer Cases, Atossa Backs Warning - StockTitan
Geode Capital Management LLC Has $4.28 Million Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Barclays PLC Has $255,000 Stock Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
State Street Corp Has $2.63 Million Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd - Defense World
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
The Manufacturers Life Insurance Company Invests $75,000 in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update - MarketBeat
Atossa Therapeutics’ (ATOS) Buy Rating Reiterated at HC Wainwright - Defense World
Atossa Therapeutics to present poster on Z-endoxifen at SABCS - Yahoo Finance
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - The Manila Times
Atossa Therapeutics to Present Poster Describing the - GlobeNewswire
Atossa Therapeutics Unveils Breakthrough Cancer Research: New Drug Combinations Show Enhanced Tumor-Fighting Power - StockTitan
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - The Manila Times
Atossa Therapeutics Announces Full Results from Phase 2 - GlobeNewswire
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically - EIN News
Atossa Therapeutics announces three posters on Phase 2 EVANGELINE trial - TipRanks
Atossa Therapeutics to Present Pharmacokinetic and - GlobeNewswire
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 - EIN News
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $7.00 at Ascendiant Capital Markets - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):